Health

India's No:1 Ranked Institute IIT Madras partners with Hyundai Motor India to launch 'Hyundai Hope for Cancer' to revolutionize Paediatric Cancer Care

CHENNAI, India, Oct. 14, 2025 /PRNewswire/ -- Indian Institute of Technology Madras (IIT Madras),India's No:1 Ranked Educational Institution, is partnering with Hyundai Motor India Foundation (HMIF), the CSR arm of Hyundai Motor India Limited (HMIL), to launch 'Hyundai Hope for Cancer' - a pionee...

2025-10-14 20:30 1088

Asia University Partners with NucleicAI to Build a Sovereign AI Life Science Data Platform

TAICHUNG, Oct. 14, 2025 /PRNewswire/ -- Asia University will partner with NucleicAI LLC , a next-generation platform and data company specializing in AI-driven genomics, precision medicine, and health intelligence, to build aSovereign AI Life...

2025-10-14 20:00 934

Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from NMPA

SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D code: 7MW4911) received IND clearance from the National Medical Products Administration (NMPA) inChina to ini...

2025-10-14 20:00 909

Clover Announces Positive Phase I Clinical Data for RSV-hMPV-PIV3 Combination Vaccines and for RSV Re-Vaccination in Older Adults

-- Results indicate potential best-in-class RSV+hMPV±PIV3 combination vaccines, with the potential ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection-- -- Increases in neutralizing antibodies of approximately 6-8 fold for RSV, 6-9 fol...

2025-10-14 18:18 991

Infosys Chosen by NHSBSA to Deliver a New Workforce Management Solution for the NHS in England and Wales

Next-Generation solution supports the NHS 10-year Health Plan and the mission to create a workforce that is fit for the future LONDON and BENGALURU, India, Oct. 14, 2025 /PRNewswire/ -- Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in next-generation di...

2025-10-14 18:02 960

Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration

- Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a Phase III randomized, double-blind, placebo-controlled, multicenter clinical trial. HONG KONG, Oct. 14, 2025...

2025-10-14 18:00 1211

Kyoto University Engineering Ph.D. Team Realizes Achievement Transformation in Chengdu; LivingPhoenix's Biomimetic Collagen Rated "International Leading-Edge"

—— Globally Pioneering POGMENT Triple-Helix Biomimetic Collagen Debuts at Chinese Biomaterials Congress 2025 CHENGDU, China, Oct. 14, 2025 /PRNewswire/ -- The 2025 Chinese Biomaterials Congress was recently held in Shaoxing,Zhejiang, gathering leading experts including academicians from the Chin...

2025-10-14 17:22 1019

Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded

MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides an update on its commercial and operational performance for the quarter ended30 September 2025 (Q3 2025). All figures are in USD unless stated otherwi...

2025-10-14 14:59 1333

Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) Presented Preclinical Data on GNTbm-TKI, a Novel Multi-tyrosine Kinase Inhibitor with Potent Immune Activation, at the 2025 ESMO Annual Meeting

TAIPEI, Oct. 14, 2025 /PRNewswire/ -- GNTbm (stock code: 7427, Taiwan) announced the preclinical data on GNTbm-TKI, a novel multi-receptor tyrosine kinase inhibitor for cancer immunotherapy. GNTbm-TKI will be presented as posters at the 2025European Society for Medical Oncology (ESMO) Annual Meet...

2025-10-14 14:26 885

2025 ACR Abstract Released! Exciting Data from Telitacicept's Phase III Clinical Study in Sjögren's Syndrome in China

* In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements in ESSDAI [EULAR (European League Against Rheumatism) Sjögren's Syndrome Disease Activity Index] compared to placebo. * Teli...

2025-10-14 13:44 473

HKEX to Introduce Hang Seng Biotech Index Futures

* Hang Seng Biotech Index Futures to launch on 28 November 2025 * New futures contracts offer risk management tools for one of the fastest growing sectors inHong Kong capital markets * SFC Transaction Levy Exemption will be applied for the first six months from launch HONG KONG, Oct. 14, 202...

2025-10-14 12:43 1525

Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14

SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the first patient has been enro...

2025-10-14 12:13 1031

PRC-Saltillo Expands Global Reach with Launch of Singapore Subsidiary

SINGAPORE, Oct. 14, 2025 /PRNewswire/ -- PRC-Saltillo, a leading provider of AAC (Augmentative and Alternative Communication) devices and support services, is proud to announce the official launch of its wholly owned subsidiary, PRC Saltillo Singapore Pte. Ltd. As PRC-Saltillo enters its 60th ye...

2025-10-14 08:00 937

NABR Comment on IUCN Determination

WASHINGTON, Oct. 14, 2025 /PRNewswire/ -- The International Union for Conservation of Nature (IUCN) issued a decision onOctober 9, 2025, to retain the "Endangered" status determination for long-tailed macaque ("LTM") monkeys ( Macaca fascicularis).

2025-10-14 06:55 1066

Compass, the revolutionary application that aims to reduce the risk of developing Type 2 diabetes

SYDNEY, Oct. 14, 2025 /PRNewswire/ -- Approximately 1 million Australian adults have Type 2 diabetes and it is estimated over 2 million people are pre-diabetic or are at high risk of developing the disease.*Miroma Project Factory (MPF) collaborated with leadin...

2025-10-14 05:07 1245

Natural Field Drives Breakthroughs in Co-loading Liposome Technology, Accelerating Upgrading of Raw Materials for Cardiovascular and Gut Health

XIAN, China, Oct. 13, 2025 /PRNewswire/ -- Natural Field has achieved new continuous research breakthroughs in co-loading liposome technology, with remarkable progress particularly in the development of co-loading Coenzyme Q10 (CoQ10) liposome and co-loading curcumin liposome raw materials. This ...

2025-10-13 23:00 1103

Visionary Holdings (Nasdaq: GV) Secures Global License for Breakthrough Stem Cell Technology Aimed at Diabetes Remission and Potential Complete Cure in a USD 150 Billion Global Market

TORONTO, Oct. 13, 2025 /PRNewswire/ -- Visionary Holdings Inc. ("GV" or the "Company"), a technology-driven multinational enterprise listed on Nasdaq (Nasdaq: GV), today announced that its wholly owned subsidiary,Visionary Holdings (Asia) Limited, has entered into a Global Product and Technology ...

2025-10-13 21:40 1499

Complete Genomics announces Gene by Gene as its newest sequencing service provider at ASHG

BOSTON, Oct. 13, 2025 /PRNewswire/ -- Complete Genomics , a leading innovator in genomic sequencing, today announced at the American Society of Human Genetics Annual Meeting that it has addedHouston-based Gene by Gene,  a leading ge...

2025-10-13 21:00 1029

NEXTBIOMEDICAL Announces First Patient Enrolled in U.S. FDA Pivotal Trial of Nexsphere-F™ for Knee Osteoarthritis Pain

* RESORB Study Marks Major Step Toward U.S. Regulatory Approval and Global Commercialization SEOUL, South Korea, Oct. 13, 2025 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based inSouth Korea, today announced the enrollment of the first patient...

2025-10-13 21:00 1034

iRegene Therapeutics announced promising NouvNeu001 Phase I clinical data

CHENGDU, China, Oct. 13, 2025 /PRNewswire/ -- iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company") is recognized as a biotechnology company pioneering chemically induced allogeneic cell therapy. iRegene's lead product, NouvNeu001, is the 1st iPSC therapy to receive IND approval from both t...

2025-10-13 21:00 923
1 ... 28293031323334 ... 874